查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586048

癌症切片检查市场：按产品类型、适应症划分 - 2025-2030 年全球预测

Cancer Biopsy Market by Product (Instruments, Kits & Consumables, Services), Type (Liquid Biopsies, Tissue Biopsies), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症切片检查市场价值为298.4亿美元，预计到2024年将达到334.8亿美元，复合年增长率为12.28%，预计到2030年将达到671.4亿美元。

癌症切片检查市场包括一系列收集组织样本以进行癌症诊断和监测的程序。切片检查对于提供癌症的明确诊断并帮助医生製定有效的治疗策略至关重要。该市场包括针活检和切片检查等传统技术，以及分析体液中生物标记的液态切片等新技术。全球癌症发生率不断上升以及对微创诊断工具的需求不断增长，强调了对切片检查的需求。切片检查用于多个最终用途领域，包括医院、诊断中心和研究机构。该市场的主要成长动力包括切片检查技术的进步、个人化医疗的持续采用以及医疗保健支出的增加。人工智慧驱动的影像诊断和分析工具的开发为简化诊断和提高准确性提供了重要机会。然而，市场面临一些限制，例如先进切片检查方法的相对成本、监管障碍以及患者不愿接受侵入性手术。挑战包括缺乏熟练的专业人员以及资源匮乏环境中的技术差距。对于公司而言，液态切片等非侵入性切片检查技术的创新至关重要，因为它们具有早期检测癌症的潜力。此外，投资自动切片检查技术和即时资料分析系统可以增强您的市场地位并有助于制定个人化治疗计划。在技​​术快速发展的推动下，市场竞争激烈，因此企业需要透过持续的研发努力来保持领先地位。至关重要的是，公司应专注于与研究机构的合作，以促进创新并扩大应用可能性。总体而言，透过优先考虑可访问性、成本效益和技术集成，公司可以有效地应对不断变化的市场环境并抓住新机会。

主要市场统计
基准年[2023] 298.4亿美元
预测年份 [2024] 334.8亿美元
预测年份 [2030] 671.4亿美元
复合年增长率（%） 12.28%

市场动态：揭示快速发展的癌症切片检查市场的关键市场洞察

供需的动态交互作用正在改变癌症切片检查市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 人们越来越偏好非侵入性手术
    • 癌症切片检查和组织切片的重要性日益增加
    • 扩大液体癌症切片检查的采用
  • 市场限制因素
    • 癌症切片检查的敏感性和特异性低
  • 市场机会
    • 切片检查设备的技术进步
    • 活性化新癌症治疗方法的研发活动
  • 市场挑战
    • 严格的监管要求和不确定的赎回场景

波特五力：驾驭癌症切片检查市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌症切片检查市场的外部影响

外部宏观环境因素在塑造切片检查市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解切片检查市场的竞争格局

对癌症切片检查市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症切片检查市场供应商的绩效评估

FPNV 定位矩阵是评估切片检查市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了切片检查市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对癌症切片检查市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对非侵入性手术的偏好日益增加
      • 癌症切片检查和组织切片的新重要性
      • 更多地采用液体癌症切片检查
    • 抑制因素
      • 癌症切片检查的敏感性和特异性较低
    • 机会
      • 切片检查设备的技术进步
      • 加强新癌症治疗方法的研发活动
    • 任务
      • 监管要求严格，赎回场景不明确
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症切片检查市场：副产品

  • 装置
  • 套件和用品
  • 服务

第七章癌症切片检查市场：按类型

  • 液态生物检体
  • 组织切片检查
    • 针吸切片
      • 空心针活检
      • 细针穿刺法
    • 切片检查

第八章癌症切片检查市场（按适应症）

  • 血癌
  • 乳癌
  • 子宫颈癌
  • 大肠直肠癌
  • 肾癌
  • 肝癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌
  • 皮肤癌

第九章美洲癌症切片检查市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太癌症切片检查市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的癌症切片检查市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Agena Bioscience, Inc.
  • Agilent Technologies Inc.
  • ANGLE PLC
  • Becton, Dickinson and Company
  • BIOCEPT, Inc.
  • Danaher Corporation
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health
  • HelioHealth
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • MDx Health
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • OncoCyte Corp
  • Personalis Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific, Inc.
  • Trovagene, Inc
Product Code: MRR-C27187914300

The Cancer Biopsy Market was valued at USD 29.84 billion in 2023, expected to reach USD 33.48 billion in 2024, and is projected to grow at a CAGR of 12.28%, to USD 67.14 billion by 2030.

The cancer biopsy market encompasses the array of procedures used to extract tissue samples for the diagnosis and monitoring of cancerous growths. Biopsies are crucial as they provide definitive cancer diagnoses, enabling physicians to devise effective treatment strategies. This market includes traditional techniques like needle and surgical biopsies, as well as emerging methods such as liquid biopsies, which analyze biomarkers in bodily fluids. The necessity of biopsies is underscored by the increasing global incidence of cancer and the growing demand for less invasive diagnostic tools. Biopsies find application across multiple end-use segments, including hospitals, diagnostic centers, and research institutes. Key growth drivers for this market include advancements in biopsy technologies, the rising adoption of personalized medicine, and increased healthcare spending. The development of AI-driven imaging and analysis tools presents significant opportunities, streamlining diagnosis and improving accuracy. However, the market faces limitations such as the relatively high cost of advanced biopsy methods, regulatory hurdles, and patient reluctance towards invasive procedures. Challenges also include the scarcity of skilled professionals and technological gaps in low-resource settings. For businesses, innovation in non-invasive biopsy techniques like liquid biopsy can be pivotal, given its potential to detect cancers at an earlier stage. Furthermore, investing in automated biopsy technologies and real-time data analysis systems can enhance market position and contribute to personalized treatment plans. The market is competitive, driven by rapid technological evolution, thus requiring companies to stay ahead with ongoing R&D efforts. It's crucial for businesses to focus on collaborations with research institutes to foster innovation and expand applicability. Overall, by prioritizing accessibility, cost-effectiveness, and technological integration, companies can effectively navigate this evolving market landscape and capitalize on emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 29.84 billion
Estimated Year [2024] USD 33.48 billion
Forecast Year [2030] USD 67.14 billion
CAGR (%) 12.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biopsy Market

The Cancer Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing preference for non-invasive procedures
    • Emerging significance of cancer biopsies and tissue sectioning
    • Growing adoption of liquid cancer biopsies
  • Market Restraints
    • Low sensitivity and specificity of cancer biopsies
  • Market Opportunities
    • Technological advancements in cancer biopsy devices
    • Increasing R&D activities for novel cancer treatments
  • Market Challenges
    • Stringent regulatory requirements and unclear reimbursement scenarios

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biopsy Market

A detailed market share analysis in the Cancer Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biopsy Market

A strategic analysis of the Cancer Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biopsy Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Agilent Technologies Inc., ANGLE PLC, Becton, Dickinson and Company, BIOCEPT, Inc., Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., GRAIL, Inc., Guardant Health, HelioHealth, Hologic, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., MDx Health, Myriad Genetics, Inc., Natera, Inc., OncoCyte Corp, Personalis Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Trovagene, Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments, Kits & Consumables, and Services.
  • Based on Type, market is studied across Liquid Biopsies and Tissue Biopsies. The Tissue Biopsies is further studied across Needle Biopsies and Surgical Biopsies. The Needle Biopsies is further studied across Core Needle Biopsy and Fine Needle Aspiration.
  • Based on Indication, market is studied across Blood Cancers, Breast Cancer, Cervical Cancers, Colorectal Cancer, Kidney Cancers, Liver Cancers, Lung Cancers, Ovarian Cancers, Pancreatic Cancers, Prostate Cancers, and Skin Cancers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing preference for non-invasive procedures
      • 5.1.1.2. Emerging significance of cancer biopsies and tissue sectioning
      • 5.1.1.3. Growing adoption of liquid cancer biopsies
    • 5.1.2. Restraints
      • 5.1.2.1. Low sensitivity and specificity of cancer biopsies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in cancer biopsy devices
      • 5.1.3.2. Increasing R&D activities for novel cancer treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and unclear reimbursement scenarios
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biopsy Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Kits & Consumables
  • 6.4. Services

7. Cancer Biopsy Market, by Type

  • 7.1. Introduction
  • 7.2. Liquid Biopsies
  • 7.3. Tissue Biopsies
    • 7.3.1. Needle Biopsies
      • 7.3.1.1. Core Needle Biopsy
      • 7.3.1.2. Fine Needle Aspiration
    • 7.3.2. Surgical Biopsies

8. Cancer Biopsy Market, by Indication

  • 8.1. Introduction
  • 8.2. Blood Cancers
  • 8.3. Breast Cancer
  • 8.4. Cervical Cancers
  • 8.5. Colorectal Cancer
  • 8.6. Kidney Cancers
  • 8.7. Liver Cancers
  • 8.8. Lung Cancers
  • 8.9. Ovarian Cancers
  • 8.10. Pancreatic Cancers
  • 8.11. Prostate Cancers
  • 8.12. Skin Cancers

9. Americas Cancer Biopsy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Biopsy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biopsy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agena Bioscience, Inc.
  • 2. Agilent Technologies Inc.
  • 3. ANGLE PLC
  • 4. Becton, Dickinson and Company
  • 5. BIOCEPT, Inc.
  • 6. Danaher Corporation
  • 7. Epigenomics AG
  • 8. Exact Sciences Corporation
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. Freenome Holdings, Inc.
  • 11. GRAIL, Inc.
  • 12. Guardant Health
  • 13. HelioHealth
  • 14. Hologic, Inc.
  • 15. Illumina, Inc.
  • 16. Laboratory Corporation of America Holdings
  • 17. Lucence Health Inc.
  • 18. MDx Health
  • 19. Myriad Genetics, Inc.
  • 20. Natera, Inc.
  • 21. OncoCyte Corp
  • 22. Personalis Inc.
  • 23. QIAGEN N.V.
  • 24. Thermo Fisher Scientific, Inc.
  • 25. Trovagene, Inc

LIST OF FIGURES

  • FIGURE 1. CANCER BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY KITS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOPSY MARKET SIZE, BY BLOOD CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOPSY MARKET SIZE, BY CERVICAL CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOPSY MARKET SIZE, BY KIDNEY CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOPSY MARKET SIZE, BY OVARIAN CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOPSY MARKET SIZE, BY PANCREATIC CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOPSY MARKET SIZE, BY SKIN CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023